ATE214603T1 - Stabile makrolide und makrolide imptstoff- zusammensetzungen - Google Patents

Stabile makrolide und makrolide imptstoff- zusammensetzungen

Info

Publication number
ATE214603T1
ATE214603T1 AT96304702T AT96304702T ATE214603T1 AT E214603 T1 ATE214603 T1 AT E214603T1 AT 96304702 T AT96304702 T AT 96304702T AT 96304702 T AT96304702 T AT 96304702T AT E214603 T1 ATE214603 T1 AT E214603T1
Authority
AT
Austria
Prior art keywords
macrolides
macrolide
stable
vaccine compositions
vaccine
Prior art date
Application number
AT96304702T
Other languages
English (en)
Inventor
Ramune Marija Cobb
Christopher Leigh Schwartzkoff
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE214603(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE214603T1 publication Critical patent/ATE214603T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/842—Clostridium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/843—Corynebacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT96304702T 1995-06-30 1996-06-26 Stabile makrolide und makrolide imptstoff- zusammensetzungen ATE214603T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60595P 1995-06-30 1995-06-30

Publications (1)

Publication Number Publication Date
ATE214603T1 true ATE214603T1 (de) 2002-04-15

Family

ID=21692234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96304702T ATE214603T1 (de) 1995-06-30 1996-06-26 Stabile makrolide und makrolide imptstoff- zusammensetzungen

Country Status (15)

Country Link
US (2) US5989566A (de)
EP (1) EP0750907B1 (de)
AR (1) AR003445A1 (de)
AT (1) ATE214603T1 (de)
AU (1) AU708464B2 (de)
BR (1) BR9602939A (de)
DE (1) DE69619894T2 (de)
DK (1) DK0750907T3 (de)
ES (1) ES2174027T3 (de)
NZ (1) NZ286896A (de)
PT (1) PT750907E (de)
RU (1) RU2213574C2 (de)
SI (1) SI0750907T1 (de)
UY (2) UY24268A1 (de)
ZA (1) ZA965539B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037178A2 (en) * 1995-05-17 1996-11-28 The International Centre Of Insect Physiology And Ecology (Icipe) Novel method of enhancing efficiency of anti-arthropod agents against blood-feeding ectoparasites
WO1997046204A2 (en) * 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
US6790445B1 (en) 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
WO1999002182A2 (en) * 1997-07-10 1999-01-21 Biotech Australia Pty. Limited Non-aqueous vaccines
US6524592B2 (en) * 1997-10-17 2003-02-25 American Home Products Corporation Veterinary vaccines
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
GB9801109D0 (en) * 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006518193A (ja) * 2003-01-16 2006-08-10 ユニバーシティ オブ バージニア パテント ファウンデーション 精子特異的リゾチーム様タンパク質
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
NZ529177A (en) * 2003-10-24 2005-12-23 Agres Ltd Administration process for a delivery device that releases the active agent over several days
US20070141086A1 (en) * 2003-11-21 2007-06-21 Ohara Michael K Use of antibiotics as vaccine adjuvants
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
AU2007245198B2 (en) * 2006-03-30 2010-08-12 Zoetis Services Llc Methods and compositions for vaccination of poultry
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090053335A1 (en) * 2007-04-13 2009-02-26 Chih-Hui Lin Herbal compositions for the inhibition of human immunodeficiency virus (hiv)
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2164862B1 (de) * 2007-06-08 2015-07-22 Australian Poultry CRC Pty Ltd Das clostridient-toxin netb
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
BR112012008185A2 (pt) * 2009-10-07 2016-08-16 Wyeth Llc composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
CN107837394A (zh) * 2011-06-24 2018-03-27 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US3885011A (en) * 1971-12-29 1975-05-20 Janssen Pharmaceutica Nv Vaccine adjuvants
SU627610A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат землаково в.п. против клюстридиозов животных и птиц
NZ193807A (en) * 1979-05-31 1983-03-15 Ici Tasman Ltd Improving the response of ruminants to clostridial vaccine by administering tetramisole or levamisole
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS62294623A (ja) * 1986-02-26 1987-12-22 Nisshin Flour Milling Co Ltd サルモネラ感染症予防剤
IE62125B1 (en) * 1986-03-12 1994-12-14 American Cyanamid Co Macrolide compounds
DE3785936T2 (de) * 1986-03-25 1993-08-26 Sankyo Co Makrolid-derivate, ihre herstellung und ihre verwendung.
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
US4988824A (en) * 1989-09-11 1991-01-29 Maulding Donald R Process for the preparation of 23-(C1-C6 alkyloxime)-LL-F28249 compounds
FR2654339B1 (fr) * 1989-11-14 1994-10-28 Mayoly Spindler Laboratoires Nouveaux derives solubles et non toxiques des macrolides polyeniques basiques, leur preparation et leurs applications.
US5262400A (en) * 1991-06-20 1993-11-16 Merck & Co., Inc. 4α-substituted avermectin derivatives
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
UY24268A1 (es) 2001-10-25
ZA965539B (en) 1998-03-30
DK0750907T3 (da) 2002-07-08
NZ286896A (en) 1998-05-27
US20020102266A1 (en) 2002-08-01
SI0750907T1 (en) 2002-08-31
AU5625696A (en) 1997-01-09
RU2213574C2 (ru) 2003-10-10
EP0750907B1 (de) 2002-03-20
EP0750907A3 (de) 1998-05-06
US6746677B2 (en) 2004-06-08
PT750907E (pt) 2002-08-30
DE69619894T2 (de) 2002-11-14
BR9602939A (pt) 1998-04-22
EP0750907A2 (de) 1997-01-02
AR003445A1 (es) 1998-08-05
US5989566A (en) 1999-11-23
ES2174027T3 (es) 2002-11-01
AU708464B2 (en) 1999-08-05
UY24281A1 (es) 1996-12-26
DE69619894D1 (de) 2002-04-25

Similar Documents

Publication Publication Date Title
DE69619894D1 (de) Stabile Makrolide und Makrolide Imptstoff-Zusammensetzungen
IT1288395B1 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
EE03976B1 (et) Erütromütsiinid ja nende valmistamise meetod
FI951003L (fi) Erytromysiinin ja atsitromysiinin 3"-desmetoksijohdannaiset
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
DK0973527T3 (da) Clarithromycinformuleringer med forlænget frigivelse
DE69630221D1 (de) Stabile alkoholisch-wässrige zusammensetzung
HUP0104489A3 (en) Stabilizated macrolides and pharmaceutical compositions containing them
DE69730092D1 (de) Photovernetzbare Siliconzusammensetzungen
DE69619826D1 (de) Abtastvorrichtung und verfahren
DE69620381D1 (de) Spielvorrichtung und system dafür
DE69602965D1 (de) Betriebsvorrichtung und methode
DE122007000087I1 (de) Adjuvanzsysteme und impfstoffe
DE69409309D1 (de) Stabile dispergierbare Siliconzusammensetzungen
DE69928296D1 (de) Stabile FSH und FSH Varianten enthaltende Arzneimitteln
DE69605094D1 (de) Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung
NO980016D0 (no) Makrolider
ATE228845T1 (de) Injektionsformulierungen von avermectinen und milbemycinen
BR9510277A (pt) Composições de silicone
DE69715951D1 (de) Dispergierbare Siliconzusammensetzungen
LV11898A (lv) Eritromicina atvasinajumi
DE69614038D1 (de) Alkenylcyclohexanderivate und flüssigkristalline Zusammensetzungen
FI943734A0 (fi) Uudet makrolidit ja niiden käyttö
DE69709876D1 (de) Kieferorthopädische und parodontologische vorrichtungen
DE69810223D1 (de) Geschlitzte Halteklammer und Verfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification